Loading..

INSYS Therapeutics, Inc. (INSY.Q) Report Analysis

Filing Date

2019-03-13

Grade by Sector

55 / 100

Rating

info-circle
Underperform - Companies with the lowest statistical likelihood of overperforming their sector & industry benchmarks

Price

info-circle

At Filling Date: USD 5.68

USD 0.042

At Filling Date: USD 5.68

EBITDA Margin %

N/A

Country

United States

Exchange

OTCPK

Website

www.insysrx.com

Market Cap

info-circle

At Filling Date: USD 421.9M

USD 3.2M

At Filling Date: USD 421.9M

Sector

Health Care

Industry

Biotechnology

Fundamental Summary

When INSYS Therapeutics released their Q4 results on 2019-03-13, the data was positive but unimpressive. While their growth and income factors looked good, the overall picture didn't show outstanding numbers. Bottom line, INSYS Therapeutics received an overall score of 55, which translates into a UNDERPERFORM ranking.

Sector Overview

INSYS Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. INSYS Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 192.5 -11.5% 70
Liabilities 235.6 8.4% 48
Price to Book -6.0 -100.1% 37
Cash & Equivalents 31.6 51.4% 90
Equity -43.1 -31331.9% 44
EBITDA -101.0 -18.9% 48
Total Revenues 82.1 -15.6% 97
Parameter Value Change Score
Return on Equity -1,077.6 -356.4% 63
Net Cashflow -0.4 97.0% 75
Capital Expenditure -6.1 13.4% 87
Asset Turnover 0.3 -3.2% 52
Free Cashflow -0.8 8.1% 78

* All values are TTM

Balance
Sheet Income
Statement Cash
Flow General
& Ratios

The below chart reflects INSYS Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While INSYS Therapeutics's peer average final assessment score stands on 68.0, INSYS Therapeutics's score is 55.

  •  INSY.Q
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
 77 0 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
 70 1 1
Amgen Inc. 130.1B 69 78 81
Hold
77
 77 2 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
 60 3 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
 79 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
 72 5 1
BioNTech SE 34.0B 75 79 72
Buy
79
 79 6 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
 57 7 1
Biogen Inc. 29.7B 76 70 66
Hold
74
 74 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
 69 9 1
Incyte Corporation 16.8B 83 73 84
Buy
86
 86 10 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
 74 11 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
 88 12 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
 60 13 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
 46 14 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
 81 15 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
 73 16 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
 81 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
 79 18 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
 60 19 1
Alkermes plc 5.0B 62 62 92
Hold
69
 69 20 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
 65 21 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
 74 22 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
 52 23 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
 47 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
 74 25 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
 61 26 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
 59 27 1
CureVac N.V. 2.6B 57 74 90
Hold
70
 70 28 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
 45 29 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
 58 30 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
 61 31 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
 45 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
 57 33 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
 64 34 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
 71 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
 76 36 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
 68 37 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
 82 38 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
 65 39 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
 64 40 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
 66 41 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
 65 42 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
 62 43 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
 59 44 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
 68 45 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
 61 46 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
 60 47 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
 54 48 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
 53 49 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
 54 50 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
 76 51 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
 54 52 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
 69 53 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
 56 54 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
 64 55 1
Merus N.V. 941.6M 70 54 71
Hold
64
 64 56 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
 65 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
 75 58 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
 67 59 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
 61 60 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
 52 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
 84 62 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
 64 63 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
 50 64 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
 65 65 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
 62 66 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
 60 67 1
Geron Corporation 566.2M 60 78 77
Hold
70
 70 68 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
 79 69 1
Immatics N.V. 538.7M 76 77 86
Buy
84
 84 70 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
 57 71 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
 61 72 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
 50 73 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
 56 74 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
 54 75 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
 59 76 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
 64 77 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
 45 78 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
 71 79 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
 78 80 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
 55 81 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
 78 82 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
 54 83 1
Anika Therapeutics, Inc.

PR

Highlights from Company’s recent Press Release
 322.7M 64 77 63
Hold
73
 73 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
 61 85 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
 59 86 1
AC Immune SA 299.8M 68 70 68
Hold
68
 68 87 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
 79 88 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
 56 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
 78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
 59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
 52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
 53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
 58 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
 47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
 66 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
 56 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. INSYS Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), INSYS Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 0.04
52W Low 0.03
52W High 6.5
5D MA 0.04
50D MA 0.04
200D MA 0.33
MACD -0.0
RSI 0.22
STOCH 33.33
INSY.Q Chart by TradingView

Balance Sheet Analysis

Several numbers from INSYS Therapeutics's current balance sheet were concerning, in two areas in particular: Book Value Factors and Equity. INSYS Therapeutics's price to book ratio (P/B) was reported as -6.0 and represents -100.1% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 24.5%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Consequently, their book value factors movement received a grade of 37. Also, INSYS Therapeutics published concerning equity metrics for this filing. In the current report, equity stood at -43.1, which represents a -31331.9% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 3.7%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Therefore, their equity movement component earned a score of 44. That said, one metric, Cash & Equivalents, stood out as strongly positive. INSYS Therapeutics's management was effective in improving its cash and cash equivalents metrics, which now sit at 31.6. This represents 51.4% change from the last reporting period. This performance is significantly more impressive than its peers and competitors. It suggests that their stock price has room to grow to reflect its actual intrinsic value. Therefore, its cash and cash equivalents movement earned a score of 90. The company's balance sheet, Therefore, earned a score of 43.

Parameter Value Change Score
Assets 192.5 -11.5% 70
Liabilities 235.6 8.4% 48
Price to Book -6.0 -100.1% 37
Cash & Equivalents 31.6 51.4% 90
Equity -43.1 -31331.9% 44
* All values are TTM

The below chart describes INSYS Therapeutics's performance as reflected on its balance sheet with respect to its peers. While INSYS Therapeutics received a balance sheet score of 43, the average of its peers stands on 68.0.

  •  INSY.Q
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 0 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 1 1
Amgen Inc. 130.1B 72 68 86 53 62 69 2 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 3 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 5 1
BioNTech SE 34.0B 75 69 64 97 73 75 6 1
Seagen Inc. 32.9B 59 68 55 43 66 61 7 1
Biogen Inc. 29.7B 57 72 92 50 76 76 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 9 1
Incyte Corporation 16.8B 71 72 95 82 79 83 10 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 11 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 12 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 13 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 14 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 15 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 16 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 17 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 18 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 19 1
Alkermes plc 5.0B 63 66 46 54 71 62 20 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 21 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 22 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 23 1
Natera, Inc. 3.6B 73 65 43 95 42 54 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 25 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 26 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 27 1
CureVac N.V. 2.6B 49 64 75 52 52 57 28 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 29 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 30 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 31 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 33 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 34 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 36 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 37 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 38 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 39 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 40 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 41 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 42 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 43 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 44 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 45 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 46 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 47 1
CareDx, Inc 1.2B 54 67 52 39 51 52 48 1
Vericel Corporation 1.1B 51 65 56 53 61 57 49 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 50 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 51 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 52 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 53 1
MannKind Corporation 957.2M 79 59 50 40 64 57 54 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 55 1
Merus N.V. 941.6M 59 68 50 83 81 70 56 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 58 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 59 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 60 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 62 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 63 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 64 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 65 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 66 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 67 1
Geron Corporation 566.2M 69 72 37 59 62 60 68 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 69 1
Immatics N.V. 538.7M 56 70 84 95 73 76 70 1
Agenus Inc. 520.5M 73 62 37 55 60 54 71 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 72 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 73 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 74 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 75 1
Affimed N.V. 415.0M 56 66 63 56 47 54 76 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 77 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 78 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 79 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 80 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 81 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 82 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 83 1
Anika Therapeutics, Inc.

PR

Highlights from Company’s recent Press Release
 322.7M 76 68 63 64 65 64 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 85 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 86 1
AC Immune SA 299.8M 84 64 47 53 75 68 87 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 88 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 97 1

Income Statement Analysis

Two metrics jump up as the most significant positive drivers of the income statement's strength in INSYS Therapeutics's recent report: Revenue Efficiency and Return Factors. INSYS Therapeutics reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 14.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 97. Also, Return factors metrics and ratios were exceptional in this report. INSYS Therapeutics reported a return on equity (ROE) ratio of -1077.6, representing a change of -356.4% from the last report. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Therefore, its return factors component earned a score of 63. That said, one metric, EBITDA, stood out as strongly negative. INSYS Therapeutics's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -101.0, which represents a -18.9% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 18.1%. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 48. Consequently, their income statement earned a rank of 70.

Parameter Value Change Score
EBITDA -101.0 -18.9% 48
Total Revenues 82.1 -15.6% 97
Return on Equity -1,077.6 -356.4% 63
* All values are TTM

The below chart describes INSYS Therapeutics's performance as reflected on its income statement with respect to its peers. While INSYS Therapeutics received a income statement score of 70 , the average of its peers stands on 70.0.

  •  INSY.Q
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 0 1
Silence Therapeutics plc 313.4M 83 64 69 72 1 1
Amgen Inc. 130.1B 74 75 64 78 2 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 3 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 5 1
BioNTech SE 34.0B 41 89 75 79 6 1
Seagen Inc. 32.9B 54 65 70 62 7 1
Biogen Inc. 29.7B 90 57 73 70 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 9 1
Incyte Corporation 16.8B 59 77 60 73 10 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 11 1
United Therapeutics Corporation 10.6B 57 91 54 82 12 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 13 1
Exact Sciences Corporation 7.2B 57 67 54 62 14 1
Exelixis, Inc. 6.7B 54 91 54 81 15 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 16 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 17 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 18 1
Ascendis Pharma A/S 5.2B 38 68 46 54 19 1
Alkermes plc 5.0B 69 55 81 62 20 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 21 1
Novavax, Inc. 4.0B 41 89 54 75 22 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 23 1
Natera, Inc. 3.6B 52 51 78 52 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 25 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 26 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 27 1
CureVac N.V. 2.6B 45 83 71 74 28 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 29 1
Insmed Incorporated 2.4B 51 58 73 57 30 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 31 1
Abgenix Inc. 2.1B 47 47 47 47 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 33 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 34 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 36 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 37 1
Xencor, Inc. 1.6B 42 94 52 79 38 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 39 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 40 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 41 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 42 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 43 1
Veracyte, Inc. 1.4B 45 63 57 55 44 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 45 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 46 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 47 1
CareDx, Inc 1.2B 61 44 82 50 48 1
Vericel Corporation 1.1B 76 44 82 56 49 1
IVERIC bio, Inc. 1.1B 84 58 79 70 50 1
FibroGen, Inc. 1.0B 48 74 63 67 51 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 52 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 53 1
MannKind Corporation 957.2M 95 48 56 61 54 1
ImmunoGen, Inc. 946.1M 40 73 71 64 55 1
Merus N.V. 941.6M 48 60 59 54 56 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 58 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 59 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 60 1
Amarin Corporation plc 734.5M 95 44 82 63 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 62 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 63 1
CTI BioPharma Corp. 603.6M 84 50 62 59 64 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 65 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 66 1
AnaptysBio, Inc. 586.3M 97 50 77 68 67 1
Geron Corporation 566.2M 89 67 73 78 68 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 69 1
Immatics N.V. 538.7M 37 93 53 77 70 1
Agenus Inc. 520.5M 57 83 45 74 71 1
Radius Health, Inc. 499.8M 94 71 68 82 72 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 73 1
Vaxart, Inc. 440.0M 99 51 72 68 74 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 75 1
Affimed N.V. 415.0M 95 49 75 66 76 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 77 1
MiMedx Group, Inc. 391.5M 87 43 83 59 78 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 79 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 80 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 81 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 82 1
Zymeworks Inc. 324.7M 58 53 77 56 83 1
Anika Therapeutics, Inc.

PR

Highlights from Company’s recent Press Release
 322.7M 63 80 62 77 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 85 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 86 1
AC Immune SA 299.8M 83 61 65 70 87 1
Precigen, Inc. 299.1M 57 87 59 79 88 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 97 1

Cash Flow Analysis

Overall, INSYS Therapeutics's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. INSYS Therapeutics's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. INSYS Therapeutics recorded CapEx of -6.1, which represents 13.4% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. The company's CapEx movement, therefore, received a grade of 87. Also, Free cash flow numbers published by INSYS Therapeutics were -0.8, which was a 8.1% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 4.9%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. The company's free cash flow movement, therefore, received a grade of 78. On the other hand, Asset Turnover, jumped out as looking rather underwhelming. INSYS Therapeutics's asset turnover numbers were discouraging, reflecting significant concerns related to management's ability to leverage assets to generate sales effectively and efficiently. INSYS Therapeutics recorded asset turnover of 0.3, which represents a -3.2% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 6.7 percent by this parameter. Their lackluster asset turnover metrics, specifically in contrast to leading industry peers' performance, could present significant headwinds. Underwhelming results in asset turnover metrics often lead to negative pressure in stock prices, so we rated its asset turnover momentum 52. Therefore, the company's cash flow earned a grade of 73.

Parameter Value Change Score
Net Cashflow -0.4 97.0% 75
Capital Expenditure -6.1 13.4% 87
Asset Turnover 0.3 -3.2% 52
Free Cashflow -0.8 8.1% 78
* All values are TTM

The below chart describes INSYS Therapeutics's performance as reflected on its cash flow with respect to its peers. While INSYS Therapeutics received a cash flow score of 73, the average of its peers stands on 66.0.

  •  INSY.Q
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 0 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 1 1
Amgen Inc. 130.1B 80 74 67 74 81 2 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 3 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 4 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 5 1
BioNTech SE 34.0B 73 97 50 52 72 6 1
Seagen Inc. 32.9B 53 53 50 87 58 7 1
Biogen Inc. 29.7B 58 54 90 73 66 8 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 9 1
Incyte Corporation 16.8B 78 79 92 74 84 10 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 11 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 12 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 13 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 14 1
Exelixis, Inc. 6.7B 79 90 89 83 87 15 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 16 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 17 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 18 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 19 1
Alkermes plc 5.0B 89 95 76 80 92 20 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 21 1
Novavax, Inc. 4.0B 62 38 63 54 60 22 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 23 1
Natera, Inc. 3.6B 52 54 56 84 58 24 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 25 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 26 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 27 1
CureVac N.V. 2.6B 87 80 90 70 90 28 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 29 1
Insmed Incorporated 2.4B 79 80 61 89 82 30 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 31 1
Abgenix Inc. 2.1B 66 53 45 59 58 32 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 33 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 34 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 35 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 36 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 37 1
Xencor, Inc. 1.6B 96 95 70 95 98 38 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 39 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 40 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 41 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 42 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 43 1
Veracyte, Inc. 1.4B 90 95 46 46 82 44 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 45 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 46 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 47 1
CareDx, Inc 1.2B 98 84 40 50 86 48 1
Vericel Corporation 1.1B 64 46 59 73 65 49 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 50 1
FibroGen, Inc. 1.0B 86 74 48 87 84 51 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 52 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 53 1
MannKind Corporation 957.2M 77 56 43 37 66 54 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 55 1
Merus N.V. 941.6M 70 71 74 53 71 56 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 57 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 58 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 59 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 60 1
Amarin Corporation plc 734.5M 52 40 74 55 55 61 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 62 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 63 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 64 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 65 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 66 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 67 1
Geron Corporation 566.2M 78 68 49 81 77 68 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 69 1
Immatics N.V. 538.7M 82 95 56 99 86 70 1
Agenus Inc. 520.5M 57 43 52 77 58 71 1
Radius Health, Inc. 499.8M 64 40 37 56 57 72 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 73 1
Vaxart, Inc. 440.0M 72 56 53 38 65 74 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 75 1
Affimed N.V. 415.0M 72 57 95 43 74 76 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 77 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 78 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 79 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 80 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 81 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 82 1
Zymeworks Inc. 324.7M 52 65 45 83 57 83 1
Anika Therapeutics, Inc.

PR

Highlights from Company’s recent Press Release
 322.7M 69 67 70 51 63 84 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 85 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 86 1
AC Immune SA 299.8M 66 77 79 63 68 87 1
Precigen, Inc. 299.1M 82 75 37 85 74 88 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.